Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Slabber

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1970
Absorbed dose calculations for 113mIn placental scanningE J van der Merwe, M G Lotter, P D van Heerden, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|November 29, 1980
[Severe Rh-isoimmunization and intensive plasma exchange during pregnancy]A D Heyns, H J Odendaal, C F Slabber, et al.
British Journal of Cancer|October 13, 2006
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapyM Campone, H Cortes-Funes, D Vorobiof, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1970
Absorbed dose calculations for 113mIn placental scanningE J van der Merwe, M G Lotter, P D van Heerden, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|November 29, 1980
[Severe Rh-isoimmunization and intensive plasma exchange during pregnancy]A D Heyns, H J Odendaal, C F Slabber, et al.
British Journal of Cancer|October 13, 2006
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapyM Campone, H Cortes-Funes, D Vorobiof, et al.
Pageof 6